June 20, 2014

Kite Pharma Announces Pricing of Initial Public Offering

June 19, 2014

Capricor Therapeutics Speaks at Panel on Regulation of Stem Cell-Derived Therapeutic Products at DIA 2014 50th Annual Meeting

May 29, 2014

Arno Therapeutics to Present at the Jefferies 2014 Global Healthcare Conference

May 28, 2014

Capricor Therapeutics to Present on Exosomes as a Basis for Innovative Platform Technology at 11th International Symposium on Stem Cell Therapy and Cardiovascular Innovations

May 15, 2014

Arno Therapeutics Reports First Quarter 2014 Financial and Business Update

May 15, 2014

Capricor Therapeutics Reports First Quarter 2014 Business Highlights

May 14, 2014

Arno Therapeutics to Outline Two Phase I Studies Evaluating Onapristone in Men’s and Women’s Cancers at 2014 ASCO Annual Meeting

May 14, 2014

Capricor Therapeutics to Hold First Quarter 2014 Business Update Conference Call on May 15, 2014 at 4:30 p.m. Eastern Time

May 6, 2014

Capricor Therapeutics Enters Into Exclusive License With Cedars-Sinai Medical Center for Exosome-Related IP Portfolio

May 5, 2014

Arno Therapeutics Announces Clinical Abstracts Accepted at 2014 ASCO Annual Meeting

April 14, 2014

Kite Pharma Expands Leadership Team and Announces Senior Management Promotions

April 11, 2014

Kite Pharma Expands Company’s Board of Directors with the Appointment of Jonathan M. Peacock

April 7, 2014

Arno Therapeutics Enrolls First Patient in a Phase I/II Trial Evaluating Onapristone in Men with Advanced Castration-Resistant Prostate Cancer

April 2, 2014

Kite Pharma Announces the Appointment of Arie Belldegrun, M.D., as President and Chief Executive Officer

April 1, 2014

Arno Therapeutics Reports 2013 Financial Results and Provides Update on Strategic and Operational Milestones

March 31, 2014

Kite Pharma Announces FDA Orphan Drug Designation for Anti-CD19 T Cell Cancer Immunotherapy Product

March 28, 2014

Capricor Therapeutics to Present ALLSTAR Phase I Trial Data at ACC Annual Meeting 2014

March 26, 2014

Arno Therapeutics to Present Three New Studies Supporting the Clinical Development of Onapristone at AACR Annual Meeting 2014

March 24, 2014

Arno Therapeutics Board of Directors Appoints Randy Thurman as Vice Chairman

March 10, 2014

Capricor Therapeutics to Present at Two Upcoming Investor Conferences

March 5, 2014

Arno Therapeutics to Present at 26th Annual ROTH Conference

March 4, 2014

Arno Therapeutics Granted Exclusive License for Oncology Diagnostic Technique by University of Minnesota

February 27, 2014

Arno Therapeutics Appoints Lawrence A. Kenyon Chief Financial Officer

January 21, 2014

Arno Therapeutics Enrolls First Patient in a Phase I Trial to Evaluate Lead Compound Onapristone in Progesterone Receptor Positive Solid Tumors

January 17, 2014

Kite Pharma Appoints Rizwana F. Sproule, Ph.D., as Vice President, Regulatory Affairs